Does Inavolisib belong to which type of targeted drug PI3K inhibitor?

Inavolisib (Inavolisib) is a new type of small molecule targeted drug, which belongs to the phosphatidylinositol3-kinase (PI3K Selective PI3Kalpha (PI3K-alpha) inhibitors. It mainly targets PIK3CA gene mutations, which are very common in a variety of solid tumors, especially breast cancer. By inhibiting the key pathway of PI3Kα, inalisate can effectively block the growth signals of tumor cells and achieve the effect of inhibiting tumor progression. It is an important targeted drug in the field of precision medicine.

The PI3K pathway plays an important role in the occurrence and development of tumors, especially the PI3Kα isoform, which is the main kinase driven by PIK3CA mutations. As a highly selective PI3K α inhibitor, inaliset is different from previous pan-PI3K inhibitors in that it has strong selectivity and few off-target effects, so it has less impact on normal cells while controlling tumor growth. This property makes inaliset more advantageous in terms of tolerability and safety, making it more suitable for long-term treatment.

Currently, inalise is mainly used to treat PIK3CA mutated hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer. In a pivotal Phase III clinical trial, it was shown to significantly extend progression-free survival (PFS) when combined with fulvestrant, particularly in patients who had failed prior treatment with a CDK4/6 inhibitor. This also provides new treatment options for breast cancer patients who are resistant to CDK4/6 inhibitors.

In general, as a selective inhibitor of PI3Kα, inaliset not only fills the gap in the treatment of PIK3CA mutated breast cancer, but also represents another progress in precision targeted therapy. In the future, with the continuous accumulation of clinical data and the expansion of indications, it is expected to play a role in the treatment of more solid tumors related to the PI3K pathway, opening up broader prospects for precision tumor treatment.

Reference materials:https://www.drugs.com/